Standard BioTools Reports Exit/Disposal Costs
Ticker: LAB · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1162194
| Field | Detail |
|---|---|
| Company | Standard Biotools Inc. (LAB) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $7.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, corporate-action
TL;DR
Standard BioTools is shedding some costs related to exits/disposals as of Sept 13.
AI Summary
Standard BioTools Inc. filed an 8-K on September 17, 2025, reporting on cost associated with exit or disposal activities as of September 13, 2025. The filing does not specify the exact nature or financial impact of these exit or disposal activities.
Why It Matters
This filing indicates potential restructuring or divestiture activities within Standard BioTools, which could impact future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates potential restructuring or divestiture activities, which inherently carry risks related to execution and financial impact.
Key Players & Entities
- STANDARD BIOTOOLS INC. (company) — Registrant
- FLUIDIGM CORP (company) — Former Company Name
- September 13, 2025 (date) — Date of earliest event reported
- September 17, 2025 (date) — Filing Date
FAQ
What specific activities are associated with the exit or disposal costs reported by Standard BioTools?
The filing does not specify the exact nature of the exit or disposal activities.
What is the total dollar amount associated with these exit or disposal costs?
The filing does not disclose a specific dollar amount for the exit or disposal costs.
When did the exit or disposal activities occur?
The costs are associated with activities as of September 13, 2025.
What is the primary business of Standard BioTools Inc.?
Standard BioTools Inc. is in the business of Laboratory Analytical Instruments.
Has Standard BioTools Inc. undergone a name change previously?
Yes, the company was formerly known as FLUIDIGM CORP, with a date of name change on November 13, 2001.
Filing Stats: 718 words · 3 min read · ~2 pages · Grade level 14.1 · Accepted 2025-09-17 16:05:26
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob
- $7.5 million — and related costs, to be approximately $7.5 million. These estimates are subject to a numbe
Filing Documents
- lab-20250913.htm (8-K) — 48KB
- 0001193125-25-206150.txt ( ) — 190KB
- lab-20250913.xsd (EX-101.SCH) — 51KB
- lab-20250913_htm.xml (XML) — 5KB
05. Costs Associated with Exit or Disposal Activities
Item 2.05. Costs Associated with Exit or Disposal Activities On September 13, 2025, Standard BioTools Inc. (the "Company") commenced a restructuring plan, including a reduction-in-force of approximately 15% of its total global workforce. The purpose of this restructuring plan, including the reduction-in-force, is to improve operational efficiency and reduce operating costs of its continuing operations in line with the Company's current revenue projections, while supporting the execution of the Company's long-term strategic plan. The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $7.5 million. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the operational restructuring plan, including the reduction-in-force. The Company expects these costs to be payable over the next several months. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the expected costs and timing of costs associated with the reduction-in-force, expected reductions of operating expenses, and the Company's expectations with respect to current revenue projections. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Company's costs may be